Research progress on immune checkpoint inhibitors for the treatment of mismatch re-pair-deficient/microsatellite instability-high gastric cancer
10.12354/j.issn.1000-8179.2024.20240599
- VernacularTitle:免疫检查点抑制剂治疗错配修复缺陷/微卫星高度不稳定型胃癌的研究进展
- Author:
Liu QINGHUA
1
;
Wang HAOHAO
;
Chen QINGJIE
;
Luo RUIYING
;
Luo CHANGJIANG
Author Information
1. 兰州大学第二医院普外科(兰州市 730000)
- Keywords:
mismatch repair-deficient/microsatellite instability-high(dMMR/MSI-H)gastric cancer;
immune checkpoint inhibitors(ICIs);
drug resistance
- From:
Chinese Journal of Clinical Oncology
2024;51(11):580-584
- CountryChina
- Language:Chinese
-
Abstract:
Mismatch repair-deficient/microsatellite instability-high(dMMR/MSI-H)gastric cancer represents a distinct molecular subtype of tumors characterized by pronounced sensitivity to immune checkpoint inhibitors(ICIs)attributed to its unique immune microenvironment and elevated mutation burden.Various clinical studies underscore the efficacy of ICIs in treating dMMR/MSI-H gastric cancer;however,chal-lenges such as primary and acquired resistance persist.Overcoming resistance and identifying optimal ICIs for its treatment remain critical clinical issues.This review delineates the mechanisms of ICIs,recent advances in their therapeutic application for dMMR/MSI-H gastric can-cer,and ongoing challenges in combating resistance,aiming to guide clinical practice effectively.
